Compare AstraZeneca plc (AZN) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Gap Inc — how do they compare? AstraZeneca plc trades at $168.56 (market cap $253.13B), while Gap Inc trades at $20.38 (market cap $7.25B). The key difference: AstraZeneca plc is far larger — about 34.9× Gap Inc's market cap, and Gap Inc pays the higher dividend (3.48%). Which is the better fit depends on your goals.
| AZN | GAP | |
|---|---|---|
Market Cap | $253.13B | $7.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $209.48 | $29.13 |
52-Week Low | $137.44 | $18.35 |
Enterprise Value | $279.37B | $10.33B |
Dividend Yield | 1.92% | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Gap Inc. (GAP) trades at $19.80, up 1.75% today, with a bearish technical signal despite neutral oscillators. The stock shows strong fundamentals with a P/E of 7.86 and net income margin of 6.25%, supported by a 10-quarter positive comp trend. Recent news highlights a digital transformation with AI-led marketing and ongoing legal investigations.
The outlook is mixed; valuation metrics suggest upside to the $27 consensus target, but near-term risks include legal probes and Athleta's turnaround pace. Earnings growth and margin expansion remain key catalysts, though investor sentiment is cautious amid bearish technicals and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
